{"schema_version":"secwatch.filing_event.v1","accession":"0001108205-22-000022","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.634505+00:00","generated_at":"2026-06-22T00:37:25.583766+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Curis Q3 net loss $13.3M, cuts ~30% of workforce to focus on emavusertib, cash runway into 2025","bullets":["Net loss of $13.3M ($0.14/shr) vs $11.1M ($0.12/shr) in Q3 2021; revenues $2.8M.","Plan to reduce workforce by ~30% and reallocate resources to emavusertib pipeline.","Cash & equivalents $98.7M as of Sep 30; expects cash runway into 2025.","Updated TakeAim Leukemia data for emavusertib to be presented at ASH 2022 (Dec 10-13).","FDA has allowed enrollment to resume in TakeAim Lymphoma and monotherapy dose finding of TakeAim Leukemia."],"urls":{"canonical":"https://secwatch.observer/filing/0001108205-22-000022","json":"https://secwatch.observer/filing/0001108205-22-000022.json","markdown":"https://secwatch.observer/filing/0001108205-22-000022.md","text":"https://secwatch.observer/filing/0001108205-22-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000110820522000022/0001108205-22-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000110820522000022/cris-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:37:25.583766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01425ebb581ddc74db9c78761d5db8fbb6962d4c","claim":"CURIS INC reported third quarter ended September 30, 2022 results: revenue $2.8 million, net income net loss of $13.3 million, EPS $0.14 per share on both a basic and diluted basis.","evidence_excerpt":"to a net loss of $31.8 million, or $0.35 per share on both a basic and diluted basis for the same period in 2021. Revenues, net for the third quarter of 2022 and 2021 were $2.8 million and $3.0 million, respectively. Revenues, net for the nine months ended September 30, 2022 were $7.3 million as compared to $7.5 million for the same period in 2021. Revenues for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820522000022/0001108205-22-000022-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$2.8 million"},{"label":"Net income","value":"net loss of $13.3 million"},{"label":"EPS","value":"$0.14 per share on both a basic and diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}